



Federal Retail Pharmacy Program Updates

Sitio web en Español para participantes del programa de vacunas COVID

Are you interested in dispensing COVID-19 antiviral therapies?

AmerisourceBergen is a network administrator for the HHS COVID-19 Therapeutic Dispensing Program and is currently partnered with Georgia. As we are selected by other states/locations, we will update you and will continue to provide additional information on the Therapeutic Dispensing program as we learn more.

Tell us if you would be interested in participating

If your pharmacy would be interested in participating in the antiviral program, please fill out this [brief form](#). We are only matched with Georgia at this time, but other states may want to partner with us in the coming weeks and the survey results will be shared to demonstrate reach of the network.

Updated information: Pfizer Adolescent/Adult Tris (gray cap, age 12+)

Information can now be found at CDC.gov: [Pfizer-BioNTech COVID-19 Vaccine \(Gray Cap\) Age 12 and Over](#).

The [Product Guide](#) has been updated to include information relevant to the Pfizer Adol/Adult Tris (Gray Cap, age 12+).

Pfizer controlant logger

Please do not return your Controlant logger until you have received a final Quality Disposition report from Pfizer. You may be asked to perform a manual data download in order for Pfizer to issue a final report. The logger must be in your possession in order to complete that process.

Questions regarding the logger Quality Disposition Report can be addressed to Pfizer at Pfizer.logistics@controlant.com.

Reminder: Pfizer shelf-life extension

FDA approved a shelf-life extension for the Pfizer Pediatric vaccine (Orange cap, 5-11 YO, diluent required) and Adol/Adult Tris (Gray Cap, age 12+, no diluent). This approval may be found at:

- [Healthcare Providers for 5-11 years of age, orange cap](#) (must dilute) (fda.gov)
- [Healthcare Providers for 12 years of age and older, gray cap](#) (no dilution) (fda.gov) and takes effect immediately.

This extension applies to frozen (ULT) inventories only.

The Fact Sheets for both orange and gray cap vials provided by the FDA now reads, “regardless of storage conditions, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons”.

The updated expiry dates for both the orange and gray cap vials based on 9 months from the date of manufacture are provided below:

Updated Pfizer Expiry Dates*	
<i>Printed Manufacturing Date</i>	<i>9-Month Expiry Date*</i>
06/2021	Feb. 28, 2022
07/2021	Mar. 31, 2022
08/2021	Apr. 30, 2022
09/2021	May 31, 2022
10/2021	Jun. 30, 2022
11/2021	July. 31, 2022
12/2021	Aug. 31, 2022
01/2022	Sept. 30, 2022
02/2022	Oct. 31, 2022

*Date of expiration always falls on the last day of the month

The QR code provided on the Pfizer Pediatric Vaccine carton provides a link to the EUA but does not provide information on expiration dates. Please follow EUA recommendations for storage:

- Pfizer 5 through 11 years of age formulation
 - If not previously thawed at 2°C to 8°C (35°F to 46°F), allow vials to thaw at room temperature [up to 25°C (77°F)] for 30 minutes.
 - Pfizer-BioNTech COVID-19 Vaccine multiple dose vials with orange caps and labels with orange borders may be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a total of 12 hours prior to dilution.
 - After dilution, the vial should be held between 2°C to 25°C (35°F to 77°F). Vials should be discarded 12 hours after dilution.
- Pfizer 12 years and older formulation.
 - Frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F). Do not store vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed, they should not be refrozen.
 - Vials may be transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. A carton of 10 vials may take up to 6 hours to thaw at this temperature.
 - Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.

All Pfizer updated Fact Sheets may be found at:

- <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine#additional>
- [Healthcare Providers for 5-11 years of age, orange cap \(must dilute\) \(fda.gov\)](#)
- [Healthcare Providers for 12 years of age and older, gray cap \(no dilution\) \(fda.gov\)](#)

Caremark coverage updates

Click [here](#) to view and download updated COVID Vaccine Medicare Advantage Organizations (MAOs) and Medicare-Medicaid Plans (MMPs) coverage updates from Caremark

Follow EUA COVID-19 vaccine dosing and administration guidelines

Please remember to follow EUA guidelines for correct vaccine dosing and administration. CDC reports that some pharmacies in our network are administering incorrect vaccines for the patient's age and/or condition or are not adhering to guidelines on timing between doses, including booster doses. Also, please carefully select the correct COVID-19 vaccine NDC in your pharmacy system. Double-check that the NDC selected is for the correct dose (pediatric or adult) and matches the correct vaccine brand administered. Please refer to the link below for the most up-to-date vaccine dosing and administration information.

Recap of Current Recommendations + Guidance:

- COVID-19 vaccines currently approved or authorized by FDA [are effective](#) in preventing serious outcomes of COVID-19, including severe disease, hospitalization, and death.
- A COVID-19 primary series vaccination is recommended for everyone aged 5 years and older in the United States for the prevention of coronavirus disease 2019 (COVID-19).
- In most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over the Janssen COVID-19 vaccine for primary and booster vaccination.
- An additional primary mRNA COVID-19 vaccine dose is recommended for moderately or severely immunocompromised people ≥ 12 years of age who received a 2-dose mRNA vaccine primary series.
- For those who received a primary series of Pfizer-BioNTech COVID-19 Vaccine:
 - People 18 years and older should receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after completing their Pfizer-BioNTech COVID-19 vaccine primary series. The Pfizer-BioNTech primary series consists of two doses, except for people who are moderately or severely immunocompromised, who should receive three doses as their primary series.
 - People 18 years and older with moderate or severe immunocompromise should receive a booster dose at least 6 months after their additional (3rd) dose.
 - People 16 through 17 years old may receive a Pfizer-BioNTech COVID-19 booster dose based on individual risks and benefits at least 6 months after completing their primary series of the Pfizer-BioNTech COVID-19 vaccine (two or three doses, as noted in the previous bullet). Note: Only the Pfizer-BioNTech COVID-19 vaccine may be administered for this booster dose; heterologous administration is not allowed for ages 16 through 17.
 - People 16 years through 17 years old with moderate or severe immunocompromise may receive a booster dose at least 6 months after their additional (3rd) dose.
- For those who received a primary series of Moderna COVID-19 Vaccine:
 - People 18 years and older should receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 6 months after their Moderna COVID-19 vaccine primary series. The Moderna primary series consists of two doses, except for people who are moderately or severely immunocompromised, who should receive three doses as their primary series.
 - People 18 years and older with moderate or severe immunocompromise should receive a booster dose at least 6 months after their additional (3rd) dose.
- For those who received a primary dose of Janssen COVID-19 Vaccine:
 - People 18 years and older should receive a booster dose of any COVID-19 vaccine (Pfizer-BioNTech, Moderna, or Janssen) at least 2 months after receipt of the Janssen COVID-19 vaccine single-dose primary regimen.

Important links:

- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)
- [COVID-19 Vaccine Booster Shots](#)
- [More information on dosing and administration](#)

New Year's Day holiday ordering and delivery cadence

Please note that over the New Year's Day holiday, there will be no deliveries.

- **No deliveries Thursday, December 30 through Tuesday, January 4.**

COVID-19 Test and Treat: How to Manage Patients Based on their Results

Earn CE when you attend the previously recorded: [Addressing the COVID-19 Crisis: An Open Forum Webinar Series for Pharmacy](#) . This webinar will discuss how pharmacists can test for COVID-19 and manage patients based on their results. Our featured speakers, Theresa Tolle, BPharm, FAPhA, owner of Bay Street Pharmacy in Sebastian, FL; and Brittany Sanders, PharmD, Co-Owner of The Pharmacy at Wellington in Little Rock, AR; will review the types of tests available and the latest recommendations for managing COVID-19 positive patients. This webinar will also include the latest information about COVID-19 oral antivirals and opportunities for pharmacy.

Reporting updates and reminders

School clinic weekly report

To capture the breadth of the work pharmacy partners are doing to support schools, CDC is asking that pharmacies submit to us on a weekly basis the information as indicated in [this brief form](#).

VaccineFinder daily report

CDC requires that participating pharmacies update VaccineFinder daily, even when a COVID-19 vaccine has not been administered that day.

If you have received a VaccineFinder reporting reminder email, it is important to begin reporting. **Pharmacies that do not consistently report daily to VaccineFinder, as per CDC requirements, will be placed on hold** and will be unable to order additional vaccine until reporting is validated. Email vaccinefinder@castlighthouse.com or call 855-886-4317 for assistance with access to your account.

LTC vaccinations weekly report

The CDC is requiring that partner pharmacies report weekly if they are administering COVID-19 vaccines at LTC clinics. Please provide the required report [here](#) each week.

Marketing opt-out form

As part of the AmerisourceBergen Federal Pharmacy Partnership Strategy for COVID-19 Vaccinations, *Good Neighbor Pharmacy* members receive marketing support through their existing marketing channels including the My GNP.com COVID-19 vaccine pharmacy locator, My GNP mobile app, MyGNP.com local pages, and Google Search Advertising. If you do not wish to receive marketing support through these channels, you may opt-out by completing [this form](#).

Questions? Continue to work with your Business Coach or Sales Executive if you have questions. Questions can also be sent to COVIDVaccines@amerisourcebergen.com.

AmerisourceBergen

